Xenon Pharmaceuticals ($XENE) Insider Trading & Smart Money Activity
Xenon Pharmaceuticals Inc. ($XENE) has 2 insider trades and 4 13F position changes on file. In the last 12 months on the open market, 2 insiders bought ($1.68M) and no insider sold, net +$1.68M.
- Insider buyers (12 mo)
- 2
- Insider sellers (12 mo)
- 0
- Net insider $ (12 mo)
- +$1.68M
- Congress trades (12 mo)
- 0
- 13F moves on file
- 4
- Analyst ratings on file
- 0
XENE insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 0 | 0 / 0 | 2 / 2 |
| Q3 2026 | 2 · $1.68M | 0 | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All XENE insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Insider | Ian MortimerPRESIDENT & CEO | Buy (Open-market buy) | 30K sh | $1.12M | -2.1% | — | |||||
| Insider | Kelly Thomas PatrickChief Financial Officer | Buy (Open-market buy) | 15K sh | $559.74K | -2.1% | — | |||||
| 13F | Driehaus Capital Management | Reduced | -47.04K sh | $271.12M | -0.4% | -3.7% | Read | ||||
| 13F | Driehaus Capital Management | Reduced | -47.04K sh | $235.45M | -0.4% | -3.7% | Read | ||||
| 13F | Avoro Capital Advisors | Added | +353.33K sh | $348.75M | -0.4% | -3.7% | Read | ||||
| 13F | Avoro Capital Advisors | Added | +353.33K sh | $302.87M | -0.4% | -3.7% | Read |
1W / 1M / 6M = how XENE moved from the trade or filing date.
Insider trading in XENE: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Ian Mortimer | PRESIDENT & CEO | 1 | +$1.12M | Sep 30, 2026 | |
| Kelly Thomas Patrick | Chief Financial Officer | 1 | +$559.74K | Sep 30, 2026 |
Institutions moving XENE (13F)
Frequently asked questions
Are XENE insiders buying or selling?
Over the last 12 months 2 insiders made 2 open-market purchases worth $1.68M and 0 insiders made 0 open-market sales worth $0, a net +$1.68M.
What is the latest insider trade in XENE?
Ian Mortimer, PRESIDENT & CEO filed a buy (open-market buy) of 30K sh worth $1.12M on Sep 30, 2026.
Which institutions changed their XENE positions?
Recent 13F filers moving the stock include Driehaus Capital Management and Avoro Capital Advisors.
Other biotechnology stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.